Soleno Therapeutics, Inc. announced that it has received $59.98825 million in funding from Woodline Partners LP, Perceptive Advisors LLC, Frazier Life Sciences Management, LP, Commodore Capital, Adage Capital Management, L.P., Nantahala Capital Management, LLC
October 01, 2023
Share
On October 2, 2023, Soleno Therapeutics, Inc. closed the transaction. The company will issue securities pursuant to exemption provided under Regulation D. The transaction included participation from 14 investors.
Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate, Diazoxide Choline Extended-Release tablets (DCCR), extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS), recently completed its Phase 3 development program. DCCR is a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. DCCRâs mode of action with targets in the brain, pancreas and fat tissue has the potential to impact complex diseases like PWS to reduce appetite, reduce food seeking, improve satiety, improve insulin and leptin resistance and reduce body fat. The Company has a Fast-Track designation for DCCR in PWS and an orphan designation for the drug in the United States and the European Union.
Soleno Therapeutics, Inc. announced that it has received $59.98825 million in funding from Woodline Partners LP, Perceptive Advisors LLC, Frazier Life Sciences Management, LP, Commodore Capital, Adage Capital Management, L.P., Nantahala Capital Management, LLC
SOLENO THERAPEUTICS, INC. 
